Page 5 - Scientific Library
Live Cell Imaging: User results with SiR-Actin & SiR-Tubulin
For one year now,  SiR-Actin and SiR-Tubulin, the second generation of tools to stain actin and tubulin in living cells, have been available on the market - and although it may sound like an overstatement,
Neuromuscular diseases: A new application for Statins?
Statins are HMG-CoA reductase inhibitors, well-known  medications for treating Hypercholesterolemia. Simvastatin is a member of this "Statin family" and controls
Fluorescent thermometer for living cells
Thousands of researchers spend time pampering their primary cells and cell lines every day, with the aim of defining their optimal cell culture conditions. Researchers are in effect trying to control
Which Histone (De)Methyltransferase modulators to choose?
Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,
How sample preparation can affect your biomarker studies (II)
In a previous post, we looked at the importance of sample preparation methods depending on the biomarker being studied (e.g. MMPs, cytokines). Today, let's focus on cell / tissue lysates.
Tip #1
Ion Channels and Cancer Immunology
Ions channels are pore-forming membrane proteins that control ion transit across the cell membrane to various stimuli. It was shown that deregulation or dysfunction of channels are clearly linked to many
Rolipram slows tau accumulation and AD
CBR-5884 - a Serine biosynthesis inhibitor for cancer research
Metabolic pathways are upregulated in cancer cells to promote their growth and proliferation. The evidence pointing to the requirement of the amino acid serine in tumorigenesis is overwhelming. Serine
Cost-efficient pre-optimized transfection reagents
The main challenge when choosing a transfection reagent is that we don't know how it will work with our own cell type of interest. It is also time consuming to find the optimal conditions. Well, here's